David Olson

David studied chemistry and biology at Union College and received his Ph.D. in chemistry from Stanford University. After his graduate work, he completed postdoctoral training in neuroscience at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. David joined the faculty at UC Davis in 2015, where he established a research program at the interface of chemistry and neuroscience. Olson Lab's research – which studies the basic mechanisms of how small molecules promote neural plasticity, and we develop novel therapeutics for treating neuropsychiatric disorders such as depression, anxiety, and addiction – led to the founding of Delix Therapeutics. Through its discovery platform, Delix has identified a class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles.